Background: In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data.
Introduction
As our understanding of the cancer biology evolves, and the accessibility to tumour genomic sequencing technologies increases, genome-driven cancer treatment emerges as a promising strategy [1] . Consequently, more and more patients undergo multigene sequencing of their cancer in the hope of finding genomic alterations that could effectively be targeted with matched drugs [2] .
With the decreasing cost and increasing ease of performing broad gene panel or whole exome sequencing rather than focused hotspot analysis of a few clinically validated targets, come the challenges of interpretation of complex sequencing readouts of both somatic and germline events in daily clinical practice. Several papers have recently highlighted the risks of overestimating the potential benefits of therapies tailored to the individual cancer genome [3, 4] . Adjusting physician and patient expectations to clinical reality is critical for maintaining trust in clinical research and providing the best care.
A major challenge for oncologists in the clinic is to distinguish between findings that represent proven clinical value or potential value based on preliminary clinical or preclinical evidence, from hypothetical gene-drug matches and findings that are currently irrelevant for clinical practice. Almost all commercial and academic laboratories that provide multigene panel sequencing of patient tumour samples report 'actionable' mutations that can fall into any of the above categories. Most multigene sequencing reporting systems do not prioritise alterations, nor do they use a standardised clinical utility-based ranking system. This lack of harmonisation in terminology and utility-based ranking creates a potential threat to precision medicine since patients could be recommended ineffective drugs matched to hypothetical (i.e. clinically unproven) targets, while alterations with proved clinical value could be missed due to lack of clear prioritisation.
The European Society for Medical Oncology (ESMO) initiated a project to propose a unified framework to classify targets for precision cancer medicine based on clinical evidence of utility. The primary aim is to aid oncologists to prioritise potential targets for clinical use when receiving reports of broad gene sequencing panels. This classification system would provide a common language that could be adopted by all the cancer medicine and drug development stakeholders to place targets within their clinical context. We recognise that as evidence is generated from clinical studies, targets will move from one tier to another. Also, a given molecular alteration can be supported by different levels of evidence in different cancer types and therefore it can fall into different clinical utility classes depending on disease context. Several institutions and organisations have proposed clinical classification systems for molecular alterations detected in cancer based on clinical relevance, as summarised in Table 1 [5] [6] [7] [8] [9] . These classifications are only partially overlapping, with greatest overlap in the top tiers, and none of them have been broadly implemented in clinical practice. Top tier designation in each system is often based on regulatory approval status in their geographic regions that introduces bias in the context of global cancer research. In lower tiers, each schema uses different principles to weigh the evidence available and therefore different classifications may assign the same alteration into discordant clinical utility categories. The vocabulary to define utility categories are also variable from system to system making it difficult to use a common terminology across reports and studies.
Understanding these limitations, ESMO has assembled a dedicated project group within its Translational Research and Precision Medicine Working Group (TR and PM WG), including authors from some of the earlier classification schemas, to propose guiding principles for a single classification system that could be used globally.
The ESMO Scale of Clinical Actionability for molecular Targets
• ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) Tier I: target suitable for routine use and recommend specific drug when specific molecular alteration is detected (Table 2) . Randomised trials provide the highest level of clinical evidence in drug development, but novel trial designs may be occasionally needed to validate the clinical relevance of infrequent molecular alterations where randomised trials are difficult to conduct.
We consider a target 'tier I-A', if prospective, randomised clinical trial data in a given tumour type has demonstrated clinically meaningful improvement of a survival end point in patients with the molecular alteration treated with a matching drug. Hallmark examples include the anti-HER2 antibody, trastuzumab, for ERBB2 (HER2) amplified breast cancer [10] [11] [12] and EGFR inhibitors for non-small-cell lung cancer (NSCLC) harbouring EGFR activating mutation [13, 14] .
'Tier I-B' targets are supported by data from prospective, non-randomised clinical trials that, while unable to provide evidence for survival improvement, have demonstrated clinically meaningful benefit as defined by the ESMO Magnitude of Clinical Benefit Scale (MCBS) 1.1 [15] in a biomarker selected sub-population. Examples of tier I-B targets include ROS1-rearrangement in NSCLC that defines eligibility for crizotinib or ceritinib therapy. Both of these compounds inhibit the anaplastic lymphoma kinase (ALK) and previously demonstrated improved survival in patients with NSCLC harbouring ALK rearrangements in randomised clinical trials (which qualifies ALK as tier I-A target for these drugs in lung cancer) [16] [17] [18] . However, crizotinib and ceritinib also inhibit the ROS receptor tyrosine kinase (ROS1) that is rearranged in 1%-2% of NSCLC through gene fusions leading to its constitutive activation. High objective tumour response rates were demonstrated with these drugs in ROS1-rearranged NSCLC in a series of single arm studies [19, 20] . Considering the rarity of this genomic alteration, conducting a large randomised trial in a timely manner to demonstrate improved survival would not have been feasible and the large clinical benefit observed in the single-arm studies was sufficient for endorsement of routine clinical use of these drugs in this rare molecularly defined subset of lung cancer.
Targets are designated 'tier I-C' if clinical trials in multiple tumour types, or basket clinical trials, have demonstrated a clinically meaningful benefit for the target-drug pair with similar magnitude of benefit across the different tumour types. In this scenario, the clinical value of a target-drug match can be accepted across cancers that harbour the target abnormality. An example is larotrectinib, an inhibitor of the neurotrophic receptor tyrosine kinase (a.k.a. tropomyosine receptor kinase, TRK) family showed substantial antitumour activity in cancers of diverse histological tumour type sharing activating fusions in TRK genes [21] . Similarly, the anti-PD1 checkpoint inhibitor pembrolizumab has shown broad, histology independent activity in mismatch repair deficient cancers [22] . It is important to remember that in basket trials, the number of patients with a given cancer type are often low; therefore, the confidence intervals around the estimated benefit in small tumour subsets is broad, consequently the true drug activity remains uncertain.
'Tier II-A' targets are supported by data from retrospective studies that demonstrate clinically meaningful benefit with a targeted drug in patients with a molecularly defined sub-population of a specific tumour type.
The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-Phosphatase and Tensin Homolog (PTEN) pathway is an oncogenic signalling network commonly deregulated in many cancers, either by aberrant activation of the pro-oncogenic genes (PIK3CA, PIK3CB, PIK3CD or AKT1) or through loss-offunction of the tumour suppressor PTEN. This latter event occurs in 40% of advanced prostate cancers. Drugs targeting this pathway by inhibiting AKT have been extensively tested in different tumour types. In a randomised phase II clinical trial, patients with advanced prostate cancer were given the pan-AKT inhibitor ipatasertib (GDC0068) or placebo combined with abiraterone acetate and steroids. While the addition of ipatasertib failed to prolong progression-free survival in the general trial population, a retrospective analysis showed a significant reduction of radiological progression risk in the sub-group of patients presenting tumours harbouring loss of PTEN protein expression [23] . This retrospective observation has led to the design of an ongoing validation phase III trial. This randomised study is now stratifying patients based on the presence or the absence of PTEN protein expression in the tumour (NCT03072238). These data may eventually provide evidence to move this target to tier I or relegate it accordingly.
We consider a target 'tier II-B' if at least one prospective clinical trial demonstrated higher tumour response rates in patients with a target molecular alteration but there is no definitive data available on improvement of the more important survival end points. An example includes a recently presented basket trial that showed strong association between the presence of activating Includes grading of evidence for resistance biomarkers mutations in the AKT1 gene (E17K) and tumour response to the AKT inhibitor AZD5363 [24, 25] . Further trial data are now necessary to assess how this increased responsiveness translates to improved patient outcome.
In target-drug matches that we consider as tier II, further investigation in clinical trials or through prospective registries is necessary before incorporating the target-drug match to routine care. 'Tier III-A' targets include alterations that define a patient population with proven benefit from a targeting agent in a specific tumour type, but the alteration is now detected in a different, previously not studied, tumour type. Therefore, while a strong rationale exists to try the targeted therapy in these patients, there is limited or no clinical evidence for efficacy in these other tumour types. These clinical scenarios are an ideal setting for prospective studies.
Vemurafenib is a B-Raf enzyme inhibitor, and significantly extends survival of patients with metastatic melanomas that harbour the tier I-A target BRAF V600E mutation [26] . The same mutation is also present in rare instances of other cancers types, but in contrast to the examples of tier I-C discussed above, the antitumour activity of vemurafenib in V600E mutated cancer has been shown to differ significantly from one tumour type to another. The most relevant example is the limited activity of vemurafenib in BRAF-mutated colorectal cancers [27] . Hence, identification of a BRAF V600E mutation will need to be interpreted in a tumour type-specific manner, not qualifying it broadly as a tier I-C target. 'Tier III-B' alterations have a predicted functional impact similar to an already studied tier I abnormality in the same gene, or in a gene with similar function, but lack sufficient supportive clinical data.
Poly(ADP-ribose) polymerase (PARP) inhibitors were tested in clinical trials in BRCA1 or BRCA2 loss-of-function germline mutated breast and ovarian cancers under the premise of synthetic lethality [i.e. two events that are not lethal separately (i.e. PARP inhibition and loss of BRCA function) become lethal when occur simultaneously] [28] [29] [30] . These trials demonstrated improved outcome and therefore germline BRCA1 or BRCA2 mutations are tier I targets in these diseases [31, 32] . Moreover, preliminary clinical data suggest antitumour activity in a subset of prostate and pancreatic cancers also carrying BRCA1/2 loss-of-function alterations [33] [34] [35] [36] . The BRCA1/2 genes are members of a large functionally related gene group that mediate homologous recombination during DNA repair. For example, PALB2 (Partner and localizer of BRCA2, a.k.a. FANCN) is a protein that interacts with BRCA2, and PALB2 loss impairs DNA repair through a similar mechanism as BRCA2 loss-of-function [37] . Hence, testing PARP inhibitors in clinical trials in patients with PALB2-deficient tumours is conceptually reasonable and qualifies PALB2 loss-of-function mutations as tier III-B.
• ESCAT Tier IV: Preclinical evidence of actionability.
'Tier IV-A' targets represent potential drug targets that are only supported by preclinical evidence showing that the alteration influences drug sensitivity in vitro or in vivo cancer models. 'Tier IV-B' targets represent pathway alterations at different molecular levels that are predicted to alter drug sensitivity based on in silico bioinformatic predictions. Tier IV targets are hypothetical and are best considered as qualifying evidence for future clinical testing. They may also be appropriate for enrichment of patients in early phase clinical trials that test new molecular entities targeting the affected pathway. Patients being considered for these studies need to be carefully informed of the lack of clinical evidence and the preliminary nature of the data available for such compounds, both from the safety and efficacy perspective, the potential risks involved and the alternative therapeutic options.
• ESCAT Tier V: Evidence of relevant antitumour activity, not resulting in clinical meaningful benefit as single treatment but supporting development of co-targeting approaches.
Tier V targets include alterations associated with responses to a matched targeted drug that do not translate into prolonged outcome; however, these could be suitable targets for combination therapy strategies. For example, over one-third of estrogen receptor-positive, HER2-negative breast cancers have activating mutations of PIK3CA. Clinical trials demonstrated that targeting PI3K leads to objective responses in patients with activating PIK3CA mutations. However, the responses did not impact outcome [38] . This may be explained by the upregulation of compensatory pathways in response to PI3K inhibition due to complex feedback mechanisms [39] . Understanding the mechanisms of adaptation to PI3K inhibitors could further lead to test effective double or triple combinations.
• ESCAT Tier X: Lack of evidence for actionability.
Tier X alterations would be those for which there is no clinical or preclinical evidence supporting their hypothetical utility as therapeutic target. These alterations should not be taken into account for clinical decisions.
Data repositories and bioinformatic tools for interpretation of genomic variants
The ESCAT provides a framework and a common terminology to assign current and future therapeutic targets into tiers that reflect their clinical utility for selecting patients for treatment with appropriate targeted therapies. The scale uses the strength of evidence from clinical studies as the basis to assign tiers to a target. As evidence accumulates, we expect that some targets will move from one tier to another. Evaluating the technical aspects of various platforms that are used for tumour genomic profiling are not the main focus of this document, but we recognise the critical importance of analytical validity for any test used in the clinic.
The development of reproducible bioinformatic tools to interpret the cancer genome is critical for successful implementation of precision medicine. The recent proliferation of software tools that function as molecular decision aids underscores the need for external validation and clinical testing of these new resources before endorsing them for clinical use.
To predict the functional relevance of new findings is a continuous challenge. Furthermore, as sequencing breadth and depth increases and as sequencing becomes cheaper and more common longitudinally through the disease course, the clinician will have to contend with the interpretation of sub-clonal driver events within or between metastatic or primary lesions. Validating the true clinical relevance and actionability of such events will prove challenging.
Multiplexed sequencing assays have dramatically changed the premise of 'one biomarker-one drug' under which precision medicine strategies were developed in the last two decades. Before, there was only a limited and pre-specified range of potential results arising from a molecular test whereas now, with next-generation sequencing technologies, previously unreported variants are routinely found. Regulatory agencies are aware of the complexities of interpreting genomic testing and the need for novel approximations to the regulatory approval process for tumour sequencing assays [40] . Only very few of the somatic mutations found in cancer genes (2% across 7000 tumours of a 28-cancer type cohort) [41] are known oncogenic events. For a small fraction of the others, there will be sufficient evidence for accepting them as not clinically relevant events, but most findings represent variants that are less studied, or even unique to a patient, for which the impact in cancer progression and potential implications for treatment selection are unknown. The establishment and application of the levels of evidence described above must be accompanied by the development and validation of tools supporting the interpretation of variants identified in each patient's tumour. In the clinical setting, this interpretation focuses on identifying predictive biomarkers of drug response.
Databases that collect and catalogue genomic abnormalities detected in human cancer are fundamental to accumulating evidence of the biological and clinical relevance of those findings. Some of the most prominent examples of such resources are listed in Table 3 . These tools would primarily focus in annotating validated oncogenic mutations and/or accumulating evidence for variants of unknown impact. An important effort was recently launched by the Global Alliance for Genomics and Health (www. ga4gh.org) to provide standards that allow users to simultaneously query several of these data repositories.
Finally, resources that collect tumour alterations and categorise them according to correlative clinical data available as prognostic of patient outcome and/or predictive biomarkers of response to specific therapies are critical. Accurate and harmonised annotation of clinical outcome data into these repositories is still partially an unmet need. Initiatives such as the AACR Project GENIE, that provide access to cancer genomic data with clinical outcome annotation for tens of thousands of cancer patients treated at multiple institutions worldwide, aim to accelerate translation of research findings to clinical benefit [42] .
Conclusions
The ESCAT aims to define clinical evidence-based criteria to prioritise cancer genomic abnormalities as markers to select patients for targeted therapies. We also offer a terminology that can be broadly applicable and help clinicians to therapeutically prioritise genomic alterations described in a tumour profiling report. Clear terminology regarding clinical utility should decrease the chance for misinterpretation of results that could lead to missed opportunities for effective treatment or over-interpretation of hypothetical targets. This clinical benefit-centred classification system offers a common language for all the actors involved in clinical cancer drug development. Its implementation in sequencing reports, tumour boards and scientific communication, can enable precise treatment decisions and facilitate discussions with patients about novel therapeutic options.
